REG - Oxford Nanopore Tech - Appointment of Francis Van Parys as CEO

Oxford Nanopore TechnologiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6196Ka&default-theme=true

RNS Number : 6196K  Oxford Nanopore Technologies plc  08 December 2025

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

Appointment of Francis Van Parys as Chief Executive Officer

8 December 2025

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new
generation of molecular sensing technology based on nanopores, today announces
the appointment of Francis Van Parys as Chief Executive Officer ("CEO").
Francis will join the Company and the Board as an Executive Director on 2
March 2026.

Francis brings more than 20 years of experience leading multi-billion-dollar
life science businesses, with a strong track record of scaling
innovation-driven organisations through commercial and operational excellence.
He is currently President and CEO of Radiometer, a global leader in acute care
diagnostics and part of Danaher Corporation. Previously, Francis held senior
leadership roles at Cytiva and GE Healthcare, driving sustained growth and
building high-performing teams across Europe, Asia, and North America.

Francis Van Parys will succeed Gordon Sanghera, who has led Oxford Nanopore
since its inception in 2005. Gordon will step down from the Board at close of
business on 2 March 2026 and will remain as an employee of the Company in an
advisory capacity through to early 2027 to ensure a smooth handover.

Duncan Tatton-Brown, Chair of Oxford Nanopore, remarked: "We are delighted to
welcome Francis Van Parys as the next CEO. We believe his global life sciences
leadership and deep regulatory expertise, combined with a proven ability to
scale innovation-driven businesses make him a strong fit for the next phase of
growth. His appointment follows a comprehensive succession process, led by the
Nomination Committee with an independent search firm. The Board looks forward
to working with Francis as he builds on strong foundations of innovation to
lead the Company into its next chapter of growth and impact.

"I would like to reiterate my thanks to Gordon for his leadership, vision and
unwavering commitment to building Oxford Nanopore over the last 20 years."

Francis Van Parys commented: "I'm excited to join Oxford Nanopore at such an
important stage in its development. The Company is delivering strong growth,
underpinned by its differentiated sensing platform and expanding global
customer base. With a substantial market opportunity ahead, I look forward to
building on this strong foundation, driving innovation that shapes trends in
global genomics and enhancing operational execution across the business to
deliver value for the Company and for all our stakeholders."

Gordon Sanghera, CEO of Oxford Nanopore, added: "Leading Oxford Nanopore for
more than two decades has been an extraordinary privilege. From an idea that
single-molecule sensing could be done differently, we've built a company that
created a new category of multi-omic analysis. I'm confident Francis will
build on the strong foundations of innovation and growth to lead Oxford
Nanopore to even greater success."

-ENDS-

Francis Van Parys is a director of Radiometer Medical ApS. There are no
further disclosures required pursuant to Listing Rule 9.4.8.

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:       ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:            media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries, to
understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAFAPEDESFEA



            Copyright 2019 Regulatory News Service, all rights reserved